In a report released today, Ryan Zimmerman from BTIG reiterated a Buy rating on Globus Medical (GMED – Research Report), with a price target of ...

Fintel reports that on January 8, 2025, BTIG downgraded their outlook for Inari Medical (NasdaqGS:NARI) from Buy to Neutral.

BofA Securities has recently resumed On Holding AG (ONON) stock to Buy rating, as announced on January 7, 2025, according to Finviz. Earlier, on December 18, 2024, Citigroup had initiated the stock to ...

BTIG Research has recently reduced Fiverr International Ltd (FVRR) stock to Neutral rating, as announced on November 4, 2024, according to Finviz. Earlier, on July 2, 2024, UBS had reduced the stock ...

BTIG raised the firm’s price target on Chefs’ Warehouse (CHEF) to $58 from $50 and keeps a Buy rating on the shares. The firm believes ...

We recently published a list of 10 Firms Post Strong Gains Amid Wall Street Bloodbath. In this article, we are going to take ...

BTIG analyst Thomas Shrader lowered the firm’s price target on Denali Therapeutics (DNLI) to $32 from $35 and keeps a Buy rating on the shares after the company announced topline data from the Phase 2 ...

Fulton Bank N.A. reduced its stake in shares of Boston Scientific Co. (NYSE:BSX – Free Report) by 1.3% in the 4th quarter, ...

Shares of Frontline plc (NYSE:FRO – Get Free Report) have been assigned an average rating of “Moderate Buy” from the six ...

BTIG raised the firm’s price target on Insulet (PODD) to $300 from $270 and keeps a Buy rating on the shares as part of a broader research note updating the firm’s models in select Medical Technology ...

Fintel reports that on January 7, 2025, BTIG initiated coverage of Hims & Hers Health (NYSE:HIMS) with a Buy recommendation.

Here are four large-cap value stocks that growth and income investors may want to consider now. History suggests they could rally this year.